



## **Anergis Completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT**

- 421 patients randomized at 38 European trial centers
- Top-line results expected in Q3, 2017

EPALINGES, Switzerland, February 8, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis' lead compound AllerT for patients with birch pollen allergy.

421 patients were randomized at 38 European trial centers in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden between September 2016 and January 2017. The study is designed to assess the efficacy and tolerability of two dosing regimens of **AllerT** In Adults with **Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis (ATIBAR)**. Patients with moderate to severe allergy to birch pollen were randomly allocated to receive one of three double-blind treatments administered as 5 subcutaneous injections over 2 months: placebo, AllerT 50 µg or AllerT 10 µg. ATIBAR is the largest field-based trial conducted so far with an ultra-fast allergy treatment for tree pollen allergy.

The ATIBAR trial was designed as a confirmatory efficacy trial with efficacy endpoints and the statistical power required to meet both European and US FDA efficacy criteria for registration trials in allergy immunotherapy. Its primary efficacy endpoint is a combined symptom and medication score assessed daily in natural conditions during birch pollen season, based on the recommendations of the European Association of Allergy and Clinical Immunology (*Allergy* 2014, 69, 854-67).

Top-line ATIBAR trial results are expected in the third quarter of 2017.

###

### **About Anergis**

Anergis SA is a Swiss biopharmaceutical company dedicated to the discovery and development of novel, ultra-fast, proprietary allergy immunotherapy products for the most prevalent allergies. Anergis' lead-product against birch pollen allergies, AllerT, is in Phase II clinical development. Two additional product candidates against ragweed pollen (AllerR) and house dust mite allergies (AllerDM) are in preclinical development.

Anergis has raised approximately CHF 52 million from private and institutional investors, including BioMedInvest, Renaissance PME, Sunstone Capital, and WJFS, Inc.



## **About Allergies**

Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “Conventional Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen. It typically requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (<30 min) anaphylactic reactions – which can be life-threatening. With its technology, Anergis is shaping the future of allergy treatment by developing therapeutic modalities that only require 2 months of treatment - compared to 3 to 5 years with currently marketed products.

## **About Ultra-fast Allergy Immunotherapy and AllerT**

AllerT is Anergis’ ultra-fast allergy immunotherapy (AIT) against birch pollen allergy originating from the company’s proprietary Contiguous Overlapping Peptide (COP) technology platform. COPs are long synthetic peptides that include the full amino acid sequence of one or more natural allergens, which are devoid of the IgE epitopes responsible for the risk of anaphylaxis during immunotherapy with allergens. COP allergy immunotherapy is “ultra-fast” because it only requires a single, 2-month course of treatment to induce long-lasting allergy symptom relief – without repeated treatment in following years.

Today, AllerT is the only ultra-fast AIT treatment with demonstrated clinical efficacy in real-life field-based trials for two consecutive annual pollen seasons and persistent statistically significant elevation in specific immunoglobulin G4 (IgG4) for four consecutive annual pollen seasons, without repeated treatment after the initial 2-month course.

### **Contact:**

Anergis SA  
CH-1066 Epalinges  
Vincent Charlon, CEO  
[info@anergis.ch](mailto:info@anergis.ch)

### **Media Inquiries:**

akampion  
Dr. Ludger Wess, Ines-Regina Buth  
Managing Partners  
Tel. +49 40 88165964 or +49 30 2363 2768  
[info@akampion.com](mailto:info@akampion.com)